Stop Progression of Fibrosis by Administration of Intermittent Continuous Treatment With Peginterferon Alfa-2a. Open-label, Randomized Efficacy and Safety Clinical Trial of Intermittent Continuous Treatment With Peginterferon Alfa-2a (PEGASYS) in Patients With HBeAg Negative Hepatitis B Responding to Prior Treatment With Interferon Alfa (SOFIA -LTT)
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms SOFIA-LTT
- Sponsors Roche
- 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Jan 2012 Planned end date changed from 1 Aug 2011 to 1 Aug 2012 as reported by ClinicalTrials.gov
- 16 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by Roche record.